Latest From Antabio SAS
The latest biopharma industry appointments include C-suite hires at Hikma, Ipsen, Sinclair PeptiDream, Targovax, Nicox, Moderna, Antabio and Perrigo; as well as a supervisory board appointment at Kiadis.
October was an active fundraising month for both start-up biopharma companies and more established privately held firms, ranging from $3m for Appili's drug for anaerobic infections to $270m for Harmony's rare disease programs.
Canaan raised $800m for tech and health care investments. Also, six companies closed VC rounds, CARB-X backed more antibiotics, CIRM funded BrainStorm and Sarepta led recent offerings.
Nosopharm SAS aims to address bacterial multidrug resistance to antibiotics, particularly in hospital-acquired gram-negative infections, using an-house drug discovery platform that exploits the microbial diversity of the bacterial genera Xenorhabdus and Photorhabdus.
- Therapeutic Areas
- Infectious & Viral Diseases
- Western Europe
- Parent & Subsidiaries
- Antabio SAS
- Senior Management
Marc Lemonnier, PhD, CEO
Martin Everett, PhD, CSO
Magdalena Zalacain, PhD, Head, Preclinical Dev.
- Contact Info
Phone: (33) 633 34 39 76
Rue Pierre et Marie Curie
P.O. Box 28262 Labege, 31682
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.